Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.

New Drug: Mirvetuximab Soravtansine in FRalpha Positive Ovarian Cancer
Single-arm, Phase-3 trial (SONAYA) Platinum-resistant epithelial ovarian cancer (up to three prior lines of systemic therapy; all patients were required to have received bevacizuma
New Drug: Enasidenib in IDH2 Mutant AML
Phase III, randomized, open-label study Patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed t
New Indication: Durvalumab with Tremelimumab in Metastatic NSCLC
Phase III, randomized, three-arm, open-label study (POSEIDON) Previously untreated mNSCLC Arm A: (T+C+CT) Tremelimumab 75 mg plus durvalumab 1,500 mg and chemotherapy for up to fou
New Protocol: Cemiplimab with Chemotherapy in NSCLC
Double-blind, placebo-controlled, phase 3 study Untreated advanced or metastatic NSCLC Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154))
New Drug: Mosunetuzumab for R/R Follicular Lymphoma
Single-arm, multicenter, phase 2 study Relapsed or refractory to two or more previous lines of treatment Mosunetuzumab q21 days (n=90)
New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer
Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 w
New Indication: Dabrafenib and Trametinib in bRAV V600E Mutant Anaplastic Thyroid Cancer
Open-label, nonrandomized, phase II basket study Unresectable or metastatic 36 anaplastic thyroid cancer patients Dabrafenib 150 mg x 2 /day plus trametinib 2 mg/day
New Protocol: Venetoclax with 3 + 7 Chemotherapy for AML
Two-stage, single-arm, phase 2 trial Previously untreated de novo acute myeloid leukaemia IV daunorubicin (60 mg/m2 on days 1-3), IV cytarabine (100 mg/m2 on days 1-7), and oral ve
New Reference: Nivolumab and Cabozantinib for Advanced RCC
Open-label, randomised, phase 3 trial (CheckMate 9ER) Previously untreated advanced or metastatic clear-cell renal cell carcinoma Nivolumab 240 mg/2 weeks plus cabozantinib 40 mg/d
Easiest Access to Our Chemotherapy Protocol Library
Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries